全文获取类型
收费全文 | 6259篇 |
免费 | 726篇 |
国内免费 | 588篇 |
出版年
2024年 | 44篇 |
2023年 | 221篇 |
2022年 | 293篇 |
2021年 | 445篇 |
2020年 | 493篇 |
2019年 | 636篇 |
2018年 | 396篇 |
2017年 | 236篇 |
2016年 | 281篇 |
2015年 | 266篇 |
2014年 | 387篇 |
2013年 | 461篇 |
2012年 | 270篇 |
2011年 | 318篇 |
2010年 | 211篇 |
2009年 | 258篇 |
2008年 | 261篇 |
2007年 | 262篇 |
2006年 | 219篇 |
2005年 | 225篇 |
2004年 | 184篇 |
2003年 | 171篇 |
2002年 | 143篇 |
2001年 | 74篇 |
2000年 | 68篇 |
1999年 | 74篇 |
1998年 | 65篇 |
1997年 | 57篇 |
1996年 | 55篇 |
1995年 | 46篇 |
1994年 | 41篇 |
1993年 | 48篇 |
1992年 | 32篇 |
1991年 | 27篇 |
1990年 | 33篇 |
1989年 | 22篇 |
1988年 | 25篇 |
1987年 | 23篇 |
1986年 | 26篇 |
1985年 | 25篇 |
1984年 | 29篇 |
1983年 | 18篇 |
1982年 | 23篇 |
1981年 | 13篇 |
1980年 | 19篇 |
1979年 | 6篇 |
1978年 | 10篇 |
1977年 | 6篇 |
1976年 | 7篇 |
1974年 | 6篇 |
排序方式: 共有7573条查询结果,搜索用时 15 毫秒
171.
172.
Hutchinson–Gilford progeria syndrome (HGPS) is caused by an LMNA mutation that results in the production of the abnormal progerin protein. Children with HGPS display phenotypes of premature aging and have an average lifespan of 13 years. We found earlier that the targeting of the transmembrane protein PLA2R1 overcomes senescence and improves phenotypes in a mouse model of progeria. PLA2R1 is regulating the JAK/STAT signaling, but we do not yet know whether targeting this pathway directly would influence cellular and in vivo progeria phenotypes. Here, we show that JAK1/2 inhibition with ruxolitinib rescues progerin‐induced cell cycle arrest, cellular senescence, and misshapen nuclei in human normal fibroblasts expressing progerin. Moreover, ruxolitinib administration reduces several premature aging phenotypes: bone fractures, bone mineral content, grip strength, and a trend to increase survival in a mouse model of progeria. Thus, we propose that ruxolitinib, an FDA‐approved drug, should be further evaluated as a drug candidate in HGPS therapy. 相似文献
173.
Qiang‐Qiang Li Jing Xi Bing‐Qiang Li Ning Li 《Journal of biochemical and molecular toxicology》2020,34(2)
The purpose of this study was to investigate the biological effect of miR‐16 on myocarditis and the underlying molecular mechanism. H9c2 cells were treated with 10 µg/mL lipopolysaccharide (LPS) for 12 hours to form a myocarditis injury model. We observed that LPS treatment distinctly decreased the level of miR‐16 in H9c2 cells. Upregulation of miR‐16 increased cell proliferation and reduced cell apoptosis. Then, CD40 was predicted and verified as a target gene of miR‐16 by TargetScan and luciferase reporter assay, respectively. Furthermore, the messenger RNA and protein expression of CD40 are negatively regulated by miR‐16. The relative expression of inflammatory factors was dramatically decreased by the miR‐16 mimic. Cells cotransfected with miR‐16 mimic and si‐CD40 could significantly abolish the injury of cardiomyocytes caused by myocarditis. Our study illustrated that the upregulation of miR‐16 has a protective effect on LPS‐damaged H9c2 cells, which may be achieved by regulating CD40 and the nuclear factor kappa B pathway. 相似文献
174.
175.
176.
Ingrid S. Garcia Susana A. Teixeira Karine A. Costa Daniele B. D. Marques Gustavo de A. Rodrigues Thaís C. Costa Jos D. Guimares Pamela I. Otto Alysson Saraiva Adriana M. G. Ibelli Maurício E. Canto Haniel C. de Oliveira Mnica C. Ledur Jane de O. Peixoto Simone E. F. Guimares 《Molecular reproduction and development》2020,87(7):819-834
177.
Jiaxin Zheng Shoulin Zhang Huijun Chen Xiaojun Cai Chunjian Zhang Shuhua Li Yabin Zhou Jing Shang Shunyu Liang Fengzhen Yao 《Cell biology international》2020,44(1):189-199
Protosappanin‐A (PrA) and oleanolic acid (OA), which are important effective ingredients isolated from Caesalpinia sappan L., exhibit therapeutic potential in multiple diseases. This study focused on exploring the mechanisms of PrA and OA function in podocyte injury. An in vitro model of podocyte injury was induced by the sC5b‐9 complex and assays such as cell viability, apoptosis, immunofluorescence, quantitative real‐time polymerase chain reaction, and western blot were performed to further investigate the effects and mechanisms of PrA and OA in podocyte injury. The models of podocyte injury were verified to be successful as seen through significantly decreased levels of nephrin, podocin, and CD2AP and increased level of desmin. The sC5b‐9‐induced podocyte apoptosis was inhibited in injured podocytes treated with PrA and OA, accompanied by increased protein levels of nephrin, podocin, CD2AP, and Bcl2 and decreased levels of desmin and Bax. The p‐AKT/p‐mTOR levels were also reduced by treatment of PrA and OA while AKT/mTOR was unaltered. Further, the effects of PrA and OA on injured podocytes were similar to that of LY294002 (a PI3K‐AKT inhibitor). PrA and OA were also seen to inhibit podocyte apoptosis and p‐AKT/p‐mTOR levels induced by IGF‐1 (a PI3K‐AKT activator). Our data demonstrate that PrA and OA can protect podocytes from injury or apoptosis, which may occur through inhibition of the abnormal activation of AKT‐mTOR signaling. 相似文献
178.
179.
The application of tyrosine kinase inhibitors (TKIs) to the epidermal growth factor receptor (EGFR) has been proven to be highly effective for non‐small‐cell lung cancer (NSCLC). However, patients often evolve into acquired resistance. The secondary mutations in EGFR account for nearly half of the acquired resistance. While the remaining 50% of patients exhibit tolerance to EGFR‐TKIs with unclear mechanism(s). Cylindromatosis (CYLD), a deubiquitinase, functions as a tumor suppressor to regulate cell apoptosis, proliferation, and immune response, and so on. The role of CYLD in NSCLC EGFR‐TKI resistance remains elusive. Here, we found CYLD was upregulated in PC‐9 cells, whereas downregulated in PC‐9 acquired gefitinib‐resistant (PC‐9/GR) cells in response to the treatment of gefitinib, which is consistent with the results in the Gene Expression Omnibus database. Overexpression of CYLD promoted a more apoptotic death ratio in PC‐9/GR cells than that in PC‐9 cells. In addition, silencing the expression of CYLD resulted in an increase of the expression level of interleukin‐6, transforming growth factor‐β and tumor necrosis factor‐α, which may contribute to acquired resistance of PC‐9 cells to gefitinib. Taken together, our data in vitro demonstrate that PC‐9/GR cells downregulated CYLD expression, enhanced subsequent CYLD‐dependent antiapoptotic capacity and inflammatory response, which may provide a possible target for acquired gefitinib‐resistant treatment in NSCLC. 相似文献
180.
Tripartite motif protein 25 (TRIM25) expression was altered in various human cancers. Herein, we found that the expression of TRIM25 was elevated in hepatocellular carcinoma (HCC) tissues and cell lines. Knockdown of TRIM25 increased the sensitivity of HCC HepG2 cells to epirubicin (EPI), as indicated by reduced cell viability, enhanced cell apoptosis, and downregulated P‐glycoprotein (P‐gp) and multiple drug‐resistance protein 1 (MRP1). Moreover, TRIM25 knockdown strengthened the effects of EPI on phosphatase and tensin homolog (PTEN) and phosphorylated (p)‐AKT. However, overexpression of TRIM25 exerted an opposite effect, weakening the sensitivity of Huh7 to EPI, and obviously increasing PTEN and reducing p‐AKT. Most important, all the changes induced by TRIM25 overexpression in Huh7 were reversed with additional treatment of LY294002 (an AKT pathway inhibitor). Notably, coimmunoprecipitation experiments confirmed the interaction between TRIM25 and PTEN. Knockdown of TRIM25 resulted in reduced ubiquitination of PTEN protein. Collectively, our data suggested that TRIM25 enhanced EPI resistance via modulating PTEN/AKT pathway, and targeting TRIM25 may enhance the sensitivity of HCC cells toward chemotherapy drugs. 相似文献